TG Therapeutics/$TGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
Ticker
$TGTX
Sector
Primary listing
Employees
399
Headquarters
Website
TG Therapeutics Metrics
BasicAdvanced
$4.1B
10.09
$2.77
1.86
-
Price and volume
Market cap
$4.1B
Beta
1.86
52-week high
$46.48
52-week low
$25.28
Average daily volume
1.7M
Financial strength
Current ratio
4.102
Quick ratio
2.911
Long term debt to equity
38.99
Total debt to equity
39.258
Interest coverage (TTM)
4.61%
Profitability
EBITDA (TTM)
123.383
Gross margin (TTM)
83.66%
Net profit margin (TTM)
72.56%
Operating margin (TTM)
20.01%
Effective tax rate (TTM)
-316.41%
Revenue per employee (TTM)
$1,540,000
Management effectiveness
Return on assets (TTM)
9.39%
Return on equity (TTM)
107.81%
Valuation
Price to earnings (TTM)
10.094
Price to revenue (TTM)
6.547
Price to book
6.57
Price to tangible book (TTM)
6.18
Price to free cash flow (TTM)
-161.494
Free cash flow yield (TTM)
-0.62%
Free cash flow per share (TTM)
-0.173
Growth
Revenue change (TTM)
87.32%
Earnings per share change (TTM)
1,746.67%
3-year revenue growth (CAGR)
504.86%
10-year revenue growth (CAGR)
129.45%
3-year earnings per share growth (CAGR)
18.78%
10-year earnings per share growth (CAGR)
7.22%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
TG Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TG Therapeutics stock?
TG Therapeutics (TGTX) has a market cap of $4.1B as of March 16, 2026.
What is the P/E ratio for TG Therapeutics stock?
The price to earnings (P/E) ratio for TG Therapeutics (TGTX) stock is 10.09 as of March 16, 2026.
Does TG Therapeutics stock pay dividends?
No, TG Therapeutics (TGTX) stock does not pay dividends to its shareholders as of March 16, 2026.
When is the next TG Therapeutics dividend payment date?
TG Therapeutics (TGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for TG Therapeutics?
TG Therapeutics (TGTX) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.